| NCT Number | NCT04930289 |
| Lead Sponsor | Paragonix Technologies |
| Conditions | Interstitial Lung Disease, COPD, Cystic Fibrosis, Pulmonary Fibrosis, Pulmonary Arterial Hypertension, Emphysema |
| Enrollment | 2,000 participants |
| Start Date | 2021-10-15 |
| Primary Completion | 2028-06-15 (estimated) |
| Study Completion | 2029-12-30 (estimated) |
| Updated on ClinicalTrials.gov | 2025-05-15 |